Pharmacokinetic interactions between digoxin and other drugs  by Marcus, Frank I.
82A JACC Vol. 5, No.5
May 1985:82A-90A
Pharmacokinetic Interactions Between Digoxin and Other Drugs
FRANK I. MARCUS, MD, FACC
Tucson, Arizona
Drug interactions with digoxin are important because of
this agent's narrow therapeutic index. Among the drugs
that can decrease digoxin bioavailability are cholestyr-
amine, antacid gels, kaolin-peetate, certain antimicro-
bial drugs and cancer chemotherapeutic agents. In
selected patients, antibiotics may enhance digoxin bio-
availability by eliminating intestinal flora that metabo-
lize digoxin.
Antiarrhythmic drugs, such as quinidine and amio-
darone, can markedly increase steady state serum dig-
oxin levels. Certain calcium channel blocking drugs,
Historical Perspective
Drug interactions with digoxin could only have been
suspected but not verified before the availability of assays
sufficiently sensitive to measure digoxin in biological fluids
(1-4). In 1971, Caldwell and Greenberger (5) investigated
the possibility that cholestyramine, an anion exchange resin
known to bind neutral sterols, might be effective in de-
creasing the duration of digitalis toxicity. Subsequently,
Smith (6) documented that cholestyramine coadministered
with digoxin could decrease digoxin absorption. Binnion
(7) also reported extremely low levels of serum digoxin in
a patient who was taking kaolin-pectate with digoxin and
identified that kaolin-pectate decreased the bioavailability
of digoxin. This led to an intensive investigation of drugs
that might decrease digoxin bioavailability. The startling
observation by Ejvinsson (8) that quinidine coadministered
with digoxin caused a marked elevation in plasma concen-
trations of digoxin led to exploration of other antiarrhythmic
drug interactions with digoxin. Subsequently, the pace of
investigation of drug interactions with digoxin has escalated
and numerous interactions with digoxin have been unveiled
(9-11).
The focus on drug interactions with digoxin is appropriate
for this agent since it not only is one of the most commonly
prescribed drugs, but also has a narrow therapeutic index.
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particularly verapamil, have a similar effect. Potassium-
sparing diuretic drugs, such as spironolactone, can alter
digoxin pharmacokinetics.
Indomethacin may decrease renal excretion of dig-
oxin in preterm infants. Finally, rifampin, an antibiotic
used in the treatment of tuberculosis, may lower steady
state serum digoxin levels in patients with severe renal
disease. Physicians must maintain constant vigilance
whenever medications are added to or withdrawn from
a therapeutic regimen that includes digoxin.
(J Am Coil CardioI1985;5:82A-90A)
There is a high incidence of toxicity during the therapeutic
use of this class of drugs. Interactions of cardiac glycosides
with other drugs contribute significantly to the high prev-
alence of digitalis toxicity. This review will focus on the
pharmacokinetic interactions of digoxin. The drugs that have
been investigated for interactions are listed in Table 1 and
their mechanisms and magnitude are summarized in Table
2.
Drugs That Affect Bioavailability of Digoxin
Cholestyramine. When 4 to 8 g of cholestyramine are
given at the same time as digoxin, there is a 25% decrease
in steady state serum digoxin levels (12). The mechanism
of this interference appears to be related to physical binding
of digoxin to the resin (5). Administration of digoxin 8 hours
before cholestyramine prevents the interference with ab-
sorption of the glycoside (12). This interaction can also be
minimized by prescribing digoxin in a solution contained
in a gelatin capsule (Lanoxicap). The Lanoxicap preparation
also produces less variability in digoxin absorption when
cholestyramine is given with the capsules as compared with
the tablets.
Antacids. Antacid gels (13), but not the tablets (14),
appear to decrease the absorption of a single dose of digoxin
by approximately 25%. The mechanism of this reduction
of digoxin absorption by antacids is unclear. Since only
magnesium trisilicate has been found to adsorb digoxin in
vitro (15) while other antacids also lowered plasma levels
in human beings, the decreased absorption of digoxin may
be due to factors other than adsorption. The effect of con-
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Table 1. Generic and Trade Names of Drugs Investigated for
Interaction With Digoxin
comitant administration of antacids and digoxin on steady
state plasma levels of digoxin remains to be established.
Until this information is available, it is advisable not to
administer digoxin at the same time as antacids.
Kaolin-pectateand bran. The decreased bioavailability
of digoxin as a result of the coadministration of an antidi-
arrheal suspension containing 18% kaolin and 0.4% pectin
(Kaopectate) was first reported by Binnion (7) after ob-
serving ineffective blood levels of digoxin in a patient who
had taken the antidiarrheal at the same time as digoxin.
Brown and Juhl (13) subsequently verified Binnion's find-
ings in a cross-over study employing 10 normal volunteers.
The magnitude of this drug interaction is still not clear since
there have been no studies to determine the effect of this
combination on steady state plasma levels of digoxin. The
decrease in digoxin absorption can be abolished by giving
digoxin 2 hours before administration of the antidiarrheal
agent (16) or may be minimized by administration of the
capsule formulation of digoxin (17).
When digoxin was given at the beginning of a meal
containing a high content of fiber, there was a 20% decrease
in cumulative 6 day urinary digoxin excretion (12). Others
(18) were not able to document a decrease in digoxin ab-
sorption when digoxin was given 15 to 30 minutes before
a meal containing high fiber content. The mechanism of this
possible interaction appears to be an adsorption of digoxin
to bran (19).
Generic Name
Cholestyramine
Kaolin-pectate
Neomycin
Sulfasalazine
Para-amino salicylic acid
Propantheline
Quinidine
Hydroxychloroquine
Amiodarone
Procainamide
Disopyramide
Mexiletine
F1ecainide
Moricizine
Verapamil
Diltiazem
Nifedipine
Tiapamil*
Nicardipine*
Gallopamil*
Lidotlazin*
Spironolactone
Triamterene
Amiloride
*U.S. trade names not now available.
Brand Name
Questran
Kaopectate
Neomycin
Azulfidine
PAS, Teebacin
Probanthine
Quinidine
Plaquenil
Cordarone
Pronestyl
Norpace
Mexitil
F1ecainide
Ethmozine
Calan; Isoptin
Cardizem
Procardia
Aldactone
Dyrenium; also in Dyazide
Midamor; also in Moduretic
Antimicrobial drugs. Certain antimicrobial drugs such
as neomycin, sulfasalazineand paraaminosalicylic acid (PAS),
often used for their effect on intestinal function and flora,
appear to depress digoxin absorption (12,20,21). This in-
teraction results in an 18 to 28% decrease in the bioavail-
ability of digoxin and is not minimized by temporal sepa-
ration of the time of administration of digoxin and the
concurrently administered antimicrobial agent.
Antibiotic treatment may increase serum digoxin levels
by an entirely different mechanism. Digoxin undergoes bio-
transformation to dihydrodigoxin and its corresponding
aglycone, dihydrodigoxigenin. These two metabolites, which
are relatively inactive, are referred to as digoxin reduction
products. Digoxin reduction products appear to be made
exclusively by bacteria in the gastrointestinal tract, probably
in the colon (22). The reduced metabolites virtually dis-
appear from the stool and urine after therapy with certain
antibiotics, and this can lead to an increase in bioavailability
of digoxin (23). In a recent study (23), a 5 day course of
erythromycin or tetracycline was found to raise the serum
digoxin concentrations by 43 to 116% in three volunteers
who produced large amounts of digoxin reduction products
(> 35 to 40% of total urinary digoxin and its metabolites).
Since only 10% of subjects produce large amounts of these
reduced derivatives, this increase in digoxin levels due to
antibioticsshould occur in only a minority of patients (22,24).
Administration of digoxin in capsule form decreases the
percent of digoxin reduction products formed, presumably
by more complete absorption of digoxin in the small intes-
tine (25). Thus, the increase in bioavailability during admin-
istration of these antibiotics should be minimized with the
use of the capsule forms of digoxin.
Drugs that alter gut motility. Digoxin absorption is
not affected by medications that alter gut motility, such as
propantheline (Probanthine) or metoclopramide (26).
Cancer chemotherapeutic agents. Digoxin absorption
and steady state levels may be markedly decreased by cancer
chemotherapy (27). This inhibition of digoxin absorption is
reversible after 1 week. The mechanism of this interaction
appears to be temporary damage of the intestinal mucosa
by the cytostatic drugs.
Interaction of Digoxin With
Antiarrhythmic Drugs
Quinidine. In 1978, Ejvinsson (8) reported that the con-
current administration of quinidine to 12 patients increased
average serum digoxin concentrations from 0.9 to 1.6 ng/ml.
One of the six patients whose plasma concentrations rose
above therapeutic range developed symptoms of digitalis
intoxication. This observation has since been amply con-
firmed (28-30). The mechanism of this interaction is com-
plex. Quinidine may enhance digoxin bioavailability (31),
although this is disputed (32). There is a decrease in the
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volume of distribution of digoxin, suggestive of a displace-
ment of digoxin binding by quinidine (33,34).
Renal and nonrenal clearance ofdigoxin. The most im-
Table 2. Pharmacokinetic Drug Interactions With Digoxin
portant mechanisms responsible for the digoxin-quinidine
interaction are a quinidine-induced reduction of both renal
and nonrenal clearances of digoxin (33-35). Since glorner-
Mechanism of Mean
Type of Study
Interaction: Magnitude Single Dose Steady Suggested
Drug Effect on Digoxin of Interaction* Digoxin State Intervention References
Cholestyramine Adsorption of ~ 25% X I) Give digoxin 8 12
digoxin hours before
cholestyramine
2) Use solution or
capsule form of
digoxin
Antacids Unclear ~ 25% X Temporal separation 13
of time of
administration
Kaolin-pectate Adsorption of ? X I) Give digoxin 2 13,16,17
digoxin hours before
kaolin-pectate
2) ? Use solution
or capsule form
of digoxin
Bran Adsorption of ~ 20% X Temporal separation 12,18
digoxin of time of
administration
Neomycin I Unknown ~ 28% X Increase dose 21Sulfasalazine ~ 18% X of digoxin 20PAS ~ 22% X 12
ErythromycinI 1 Bioavailability 143 to 116% X I) Measure serum 23,25
Tetracycline by 1 intestinal digoxin
(in <10% metabolism of concentration
of subjects) digoxin by 2) Decrease digoxin
certain gut flora dose
3) Use solution or
capsule form of
digoxin
Quinidine ? ~ Bioavailability 1100% X X I) Decrease 28-30
~ volume of dose by 50%
distribution, 2) Measure serum
~ renal and nonrenal digoxin
clearance concentration
Amiodarone ~ Renal and nonrenal 170 to 100% X Same as for 53,54,57
clearance quinidine
Verapamil ~ Renal and nonrenal 170 to 100% X Same as for 66,67
clearance quinidine
Diltiazem ? ~ Renal clearance 122% X None 71,72
Nicardipine Unknown 115% X None 76
Tiapamil Unknown 160% X Same as for 76
quinidine
Spironolactone ~ Renal and nonrenal 130% X Measure serum 86,90
clearance digoxin
concentration
Triameterene ~ Nonrenal clearance 120% X Measure serum 86
digoxin
concentration
Indomethacin ? ~ Renal clearance 150% X Decrease dose by 97
(preterm infants) 25%
*Alteration in bioavailability or serum concentration. For single dose studies, the magnitude of the anticipated change in serum digoxin concentration
was estimated from pharmacokinetic data, particularly the change in total body clearance. 1 = increased; ~ = decreased; ? = questionable.
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ular filtration rate is unchanged during concurrent digoxin-
quinidine administration, it is clear that the decreased renal
elimination of digoxin in human beings results from a quin-
idine-induced decrease in tubular secretion of digoxin (36).
Decisive evidence for a decrease in the nonrenal excretion
of digoxin under the influence of quinidine was established
by comparing the kinetics of digoxin in anuric patients on
chronic hemodialysis when given digoxin alone and con-
comitantly with quinidine (37-39) . The combination ther-
apy resulted in a rise in serum digoxin concentration in these
anuric patients .
The increase in digoxin serum concentration is directly,
but not linearly, related to the dose of quinidine (11,40).
The rate at which a new digoxin steady state is achieved is
dependent on the digoxin elimination half-life. If the half-
life of digoxin is 36 hours, approximately 7 days (1'12 days
x 5 half-lives) are required to achieve a new steady state
digoxin level. However, in patients with a glomerular fil-
tration rate of less than 50 ml/rnin , the time required for
digoxin to reach a new steady state with the addition of
quinidine may be considerably longer.
Electrophysiologic and inotropic effects. It is clear that
the elevation of digoxin levels by concurrent quinidine
admini stration results in enhanced electrophysiologic effects
demon strated on the surface electrocardiogram as a prolon-
gation of the PR interval , by central nervous system man-
ifestations of toxicity such as anorexia , nausea , vomiting
and scotomata and also by enhanced ventricular ectopic
activity (41-45) .
The elevated serum digoxin levels induced by concurrent
administration of digoxin and quinidine have been reported
not to show an enhanced inotropic effect as measured by
systolic time intervals (46-48). Schenck-Gustafsson et al.
(49), however, measured inotropic effects of digoxin at
steady state during digoxin administration alone and during
digoxin and quinidine administration . They then gave suf-
ficient digoxin to achieve a serum digoxin concentration
similar to that obtained when digoxin and quinidine were
given concomitantly . They concluded that digoxin elevation
due to quinidine was accompanied by an increased cardiac
effect.
Digitalis toxicity . Clinical evidence indicates that there
are increased electrophysiologic and inotropic effects as-
sociated with the elevation of serum digoxin as a result of
concurrent quinidine admini stration . This combination of
drugs can cause signs and symptoms of digitalis toxicity.
Therefore, the dose of digoxin should be decreased by ap-
proximately 50% and the serum digoxin levels should be
measured approximately I week after the tWQ drugs are
given together. If the dose of quinidine is increased, one
can antic ipate a further increase in serum digoxin levels.
Quinine, the I-isomer of quinidine, also reduces total
body clearance and increases the half-life of digoxin (50).
It is likely that hydroxychloroquine, a quinine derivative,
has similar interactions with digoxin (51).
Amiodarone. In 1981, Moysey et al. (52) observed a
mean increase in plasma digoxin concentration of 70% in
seven patients when amoidarone, 600 mg/day, was admin-
istered concurrently with digoxin. The mean concentration
of digoxin after amiodarone was 2 ng/ml. Four patients
developed symptoms compatible with digoxin toxicity. The
plasma digoxin level increased by 25% within 24 hours after
the initiation of amiodarone treatment. These observations
have subsequently been confirmed (53.54) . There is sugges-
tive evidence that the increase in digoxin levels may in part
be directly related to the dose of amiodarone since a linear
correlation was observed between plasma amiodarone levels
and digoxin serum levels (55) . However. a daily amiodarone
dose of 400 mg is sufficient to reduce clearance of a digoxin
concentration by 26% (56).
Mechanism. The digoxin-amiodarone interaction is due
in part to a decrease in the renal clearance of digoxin, a
decrease in nonrenal clearance and an increase in digoxin
half-life . No significant decrease in the volume of distri-
bution of digoxin was observed after amiodarone therapy
(56,57).
Digitalis toxicity . When serum digoxin levels are raised
as a result of the arniodarone-digoxin interaction, digitalis
toxicity may result. Generally, the toxic manifestations con-
sist of bradycardia or variou s degree s of atrioventricular
(AV) block rather than digitalis-toxic tachyarrhythmias
(57.58). Recommendations for digoxin dose adjustment during
concomitant amiodarone therapy are similar to those when
quinidine is given with digoxin .
Other antiarrhythmic drugs. There are several antiar-
rhythmic drugs that do not appear to have any clinically
relevant pharmacokinetic interactions with digoxin. These
include procainamide (59) , disopyramide (59-61), mexi-
letine (59,62), flecainide (63) and ethmozine (64).
Interaction of Digoxin With Calcium Channel
Blocking Drugs
The pharmacokinetic interaction between digoxin and
calcium channel blocking drugs varies from none with ni-
fedipine to an increased serum digoxin level of more than
70% when verapamil and digoxin are given concomitantly .
Verapamil. In 1980. Klein et al. (65) reported that serum
digoxin levels increased 70% during concurrent treatment
with verapamil . They found (66) that the effect of verapamil
on serum digoxin concentration developed gradually within
the first few days after verapamil was coadministered with
digoxin and approached the new steady state value within
7 days after the start of verapamil therapy. The interaction
is dose-dependent. The mechanism of the digoxin-verapamil
interaction consists of decreases in both renal and extrarenal
clearance of digoxin by verapamil (67). Since the creatinine
clearance does not change under the influence of verapamil ,
the decreased renal clearance of digoxin appears to be due
to an inhibition of tubular secretion .
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The elevated plasma digoxin concentration induced by
verapamil is associated with an inotropic effect as assessed
by a measurement of systolic time intervals (68). When the
serum digoxin levels are markedly elevated as a result of
coadministration of verapamil, lethal cardiac toxicity may
occur (69). This is more likely to take the form of severe
bradycardia or asystole, rather than initiation of the tach-
yarrhythmias that are observed when quinidine induces el-
evated serum digoxin levels (67,70). It seems prudent to
decrease the dose of digoxin by 50% when verapamil and
digoxin are given concurrently.
Diltiazem. There is minimal pharmacokinetic interac-
tion between diltiazem and digoxin (71). An average in-
crease in steady state plasma digoxin concentration of 22%
was observed when diltiazem, 180 mg/day, was given to
24 normal subjects who were receiving l3-acetyldigoxin, 0.2
mg daily (72). This interaction may be due to a diltiazem-
induced decrease in renal clearance of digoxin (71). The
magnitude of the diltiazem interaction is small; therefore,
digoxin dose adjustment is probably unnecessary.
Nifedipine. There is no pharmacokinetic interaction be-
tween nifedipine and digoxin, either in patients (73) or in
normal subjects (74,75).
Other calcium channel blocking drugs. Tiapamil, a
congener of verapamil, causes an increase in serum digoxin
levels of 60%, similar to that of verapamil (76). Nicardipine
is related to nifedipine and increases plasma digoxin min-
imally, in the order of 15%. A similar minimal increase in
digoxin levels is induced by gallopamil (77). There is no
pharmacokinetic interaction between digoxin and lidoflazine
(78).
Interaction With Diuretic Drugs
Furosemide and sodium-induced diuresis. Diuresis
induced by furosemide does not significantly affect the ex-
cretion of digoxin (79,80). However, Naafs et al. (81) re-
ported that diuresis caused a 70% increase in digoxin clear-
ance and a 20% decrease in serum digoxin levels in 10
patients who were taking digoxin for atrial fibrillation and
who did not have congestive heart failure. These subjects
were initially sodium-depleted, both by dietary restriction
of sodium as well as by diuretic drugs. When the sodium
diet was liberalized to a moderately high sodium diet, the
digoxin clearance increased by 70% and the serum digoxin
levels decreased by 20%. Mechanisms that have been iden-
tified for renal excretion of digoxin include glomerular fil-
tration, tubular secretion and proximal tubular reabsorption
of digoxin. Naafs et al. (81) postulated that one of the
mechanisms responsible for the increase in digoxin clear-
ance due to sodium loading was diminished passive prox-
imal back diffusion of filtered and secreted digoxin. Sodium
loading has been shown to diminish proximal fractional
reabsorption of glomerular ultrafiltrate. Thus, it is possible
that patients who are on a strict low sodium diet and whose
dietary sodium is increased may show some moderate de-
crease in steady state serum digoxin levels (81).
Diuresis-induced hypokalemia. Although thiazides and
loop diuretic drugs themselves do not alter the kinetics of
digoxin excretion, they induce a dose-dependent loss of
potassium from the body, resulting in a decreased serum
potassium concentration. It is well known that hypokalemia
is associated with sensitivity to digitalis and, thus, increases
its toxicity (82,83), but it is not well appreciated that when
the serum potassium is as low as 2 to 3 mEq/liter, the tubular
secretion of digoxin is nearly blocked. This reduced tubular
secretion of digoxin results in a diminished plasma clearance
of digoxin and thereby a prolonged elimination half-life of
digoxin (84,85). Thus, hypokalemia itself can result in an
increase in serum digoxin level as well as enhancing toxicity
(85).
Potassium-sparing diuretic drugs. The potassium-
sparing diuretic drugs, spironolactone, triamterene and ami-
loride, have been reported to induce changes in digoxin
kinetics (86-89). Spironolactone increases the plasma con-
centration of digoxin by inhibiting tubular secretion of di-
goxin. This results in a decrease in the renal clearance of
digoxin. The extrarenal clearance of digoxin also decreases
(88,90). In contrast, amiloride alters digoxin pharmacoki-
netics by different mechanisms. This drug causes an increase
in renal clearance, but a marked decrease in extrarenal clear-
ance. The net result is a tendency to decrease digoxin total
body clearance (87). Possible mechanisms for these obser-
vations include an increased tubular secretion of digoxin to
account for the increased renal clearance and a decrease in
the hepatic elimination rate of digoxin to account for the
decrease in extrarenal clearance. Triamterene does not alter
renal elimination of digoxin, but reduces the extrarenal
clearance of digoxin. When triamterene is given with di-
goxin, the total digoxin elimination is reduced by 20% (86).
The effects of the potassium-sparing diuretic drugs on
steady state serum digoxin levels have not been adequately
evaluated. Potassium-sparing diuretic drugs have different
mechanisms and sites of action, which may account for their
differing effects on digoxin pharmacokinetics. Spironolac-
tone exerts its effects from the capillary side of the renal
tubular cell, whereas triamterene and amiloride act on the
luminal side (91). Spironolactone does not increase intra-
cellular potassium concentration, whereas triamterene and
amiloride do.
Combined digitalis, quinidine and diuretic drug ther-
apy. Patients with cardiac disease are frequently treated
with multiple medications and the combination of a potas-
sium-sparing diuretic drug, digoxin and quinidine is not
unusual. This combination of quinidine and spironolactone
caused significant reductions in total body clearance of di-
goxin, nonrenal digoxin clearance and digoxin renal clear-
ance beyond the reductions induced by either drug alone
(90). Therefore, the effects of these two drugs on steady
state serum digoxin concentrations should be additive.
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Clinical significance. The clinical significance of an an-
ticipated elevation of steady state serum digoxin levels in-
duced by the potassium-sparing diuretic drugs is not clear.
Waldorff et al. (86,87) found that both spironolactone and
amiloride attenuated the positive inotropic effect of digitalis
evaluated by systolic time intervals and echocardiography,
whereas triamterene induced no changes in digoxin-elicited
inotropy. Since the magnitude of this interaction of potas-
sium-sparing diuretic drugs has not been established, mea-
surement of the steady state serum digoxin levels may be
warranted.
Miscellaneous Drug Interactions
With Digoxin
Anti-inflammatory drugs. No pharmacokinetic inter-
action has been observed with aspirin (92), benoxaprofen
(93) or tiaprofenic acid (94). Elevated serum levels of di-
goxin were observed after I week of concomitant therapy
with ibuprofen, but this increase in digoxin level did not
persist after 28 days (95).
Indomethacin therapy did not alter digoxin pharmaco-
kinetics in healthy adult volunteers with normal renal func-
tion (96), but was found to cause an increase of 45% in
serum digoxin levels in preterm infants when coadminis-
tered with digoxin for the treatment of patent ductus arte-
riosus (97). Administration of indomethacin to the infants
was associated with a significant decrease in urinary output,
suggesting that the increase in serum digoxin level was due
to a decreased glomerular filtration rate and a decrease in
the renal clearance of digoxin. These authors (97) suggested
that when indomethacin is added to digoxin therapy in pre-
term infants, the digoxin dose should be reduced by 50%.
The increase in serum digoxin level associated with indo-
methacin may also apply to adult patients since a lowering
of effective renal plasma flow has been observed in patients
after indomethacin administration (96). Therefore, the po-
tential for digoxin-indomethacin interaction may be greater
in patients with abnormalities in renal function.
Rifampin. Rifampin, an antibiotic used for the treat-
ment of tuberculosis, has been shown to remarkably lower
the steady state serum digoxin level in several patients de-
pendent on dialysis (98,99). There is limited evidence (98)
to suggest that this interaction is due to an increased bio-
transformation of digoxin in these patients with minimal to
no renal function. Rifampin accelerates the metabolism of
numerous drugs, including digoxin (100). Other possible
explanations for the digoxin-rifampin interaction include
decreased absorption of digoxin or increased biliary excretion.
A complex drug interaction involving rifampin. digoxin
and quinidine has been reported (1O/). Therapy with ri-
fampin produced a decline in both the serum quinidine con-
centration and serum digoxin concentration. It was postu-
lated that rifampin increased the metabolism of quinidine;
in tum, the interaction between quinidine and digoxin was
diminished, thereby lowering seurm digoxin levels. It is
possible that digoxin metabolism was directly accelerated
by rifampin. This case report (10 I) illustrates the complex
interaction that may occur with multiple drug therapy.
Cimetidine. Fraley et al. (102) reported a 25% decrease
in steady state serum digoxin concentrations when digoxin
was given together with cimetidine. These results are in
contrast to those of Jordaens et al. (103) who studied the
pharmacokinetics of oral digoxin in eight healthy volun-
teers, both with and without concurrent cimetidine. They
concluded that cimetidine had no effect on the area under
the plasma concentration versus time curve of digoxin.
Vasodilator drugs. Total renal clearance of digoxin was
increased by 50% in 8 patients during administration of
nitroprusside or hydralazine (104). Because the glomerular
filtration rate was unchanged and the estimated renal blood
flow was increased, the mechanism of this alteration in
digoxin renal clearance was thought to be an increase in
tubular secretion of digoxin. It is not yet known whether
long-term vasodilator therapy increases the dosage require-
ments for digoxin in patients with congestive heart failure.
Summary
An intensifying myriad of interactions with digoxin is
now being revealed. It is no wonder that digoxin intoxication
has been so difficult to avoid. Patients with heart disease
may be treated concomitantly with anticholesterolemic drugs,
diuretic drugs, calcium channel blocking agents, vasodila-
tors and antimicrobials, some of which have been shown to
interact with digoxin. The accumulated information regard-
ing drug interactions with digoxin should contribute to greater
safety in the use of the drug, provided that the physician
maintains constant vigilance whenever any medication is
added to or withdrawn from a therapeutic regimen that in-
dudes digoxin.
Although there has been a tremendous increase in our
knowledge of the drug interactions, more investigation is
needed to define the full scope and magnitude of these
interactions with digitalis, particularly during steady state.
We are also greatly in need of accurate and sensitive meth-
ods to reliably measure the inotropic and vagotonic effects
of digitalis to assess the effects of these drug interactions.
[ am indebted to Paul Fenster, MD and Paul Nolan, MD for critical review
of this manuscript. [ gratefully acknowledge the secretarial assistance of
Debbie Hunter.
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